OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Bought in today looks like good support at 37p

Welcome onboard. I hope that OXB proves profitable for you driver.

queen1
I top sliced some ASM its sit and wait time now for both companies.

a couple of charts specially for driver!

as always
red = 25 dma
green = 50 dma
black = 200 dma

cynic
Cheers whats your opinion.

(for Q1's benefit!) ..... I know even less than usual about this company!!

i don't like the way that both 25+50 dma are falling away quite sharply, but i do agree there should be a good chance of a bounce off the 200 dma which is still rising well especially with rsi being less than demanding.

on the way up, obvious resistance would be when sp hits underside of 25 dma at about 44

cynic
Cheers again.

NOTIFICATION OF MAJOR INTERESTS IN SHARES

http://moneyam.uk-wire.com/cgi-bin/articles/200705221553130498X.html

Is it some thing I said up 5%.

at the price you picked that up at driver you should be in profit tomorrow.........

micky468
Already in profit, but it made up for the 2p loss today on ASM but I think it was a good move.

And up we go.

To the top of the hill and

if not already invested, but tempted, then my inclination would be to wait to see if 200 dma is tested again - i.e. will it breach or bounce

cynic
I'm in this is well over sold.

certainly no obvious reason for the collapse, but that is certainly not the same as saying that peeps should rush out to buy .... one would hope that the breach of 200 dma is just a tester partially brought about by squaring of books just before b/h, but that is pure guesswork and rationalisation.

Oxford Biomedica ASCO data


RNS Number:2892X
Oxford Biomedica PLC
29 May 2007


For Immediate Release 29 MAY 2007



OXFORD BIOMEDICA AND COLLABORATORS TO PRESENT TROVAX(R) PHASE II TRIAL RESULTS
IN RENAL CANCER AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

Oxford, UK: 29 May 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, and its clinical collaborators are scheduled to deliver a poster
presentation describing results from Phase II trials of TroVax in renal cancer
at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held
on 1-5 June in Chicago, Illinois. TroVax is the Company's lead cancer
immunotherapy product, which is being developed in collaboration with
sanofi-aventis.

The presentation will include new data from two ongoing Phase II trials of
TroVax. The trials are being conducted by clinicians at the Methodist Hospital
in Houston, Texas, and are part of Oxford BioMedica's and sanofi-aventis' broad
development programme for TroVax, which includes the ongoing, multi-centre Phase
III TRIST study in renal cancer. Over 50 patients have been enrolled to date in
the Methodist Hospital's Phase II trials of TroVax in renal cancer. The trials
are designed to evaluate TroVax either as a single agent, or in combination with
either interleukin-2 or interferon-alpha. The new data will include an update on
tumour response rates, time to progression and survival. Details of the
presentation are as follows:

Session: Developmental Therapeutics: Immunotherapy. Sunday, 3 June 2007 8:00 AM
- 12:00 PM, S Hall 2 at McCormick Place, Chicago.


Activity of MVA 5T4 alone or in combination with either interleukin-2 or
interferon-alpha in patients with metastatic renal cell cancer (Abstract #3069)


The abstract may be accessed online at http://www.asco.org at the conclusion of
the meeting.


-Ends-

now see whether sp zips solidly back up through 200 dma or if it proves a stumbling block

I'm not convinced this is anything "more" than we already expected - the fall in sp is to be expected with any peaky-investment anyone that bought at 20p a few months ago ( wow, why didn't I?), will be looking at a decent profit and the ability to buy-back at significantly lower levels (well, somewhat lower). It is surprising that the fall is continuing so long - or is it?
Results aren't expected for some time and Markets keep moving about. This is a buying opportunity for some - maybe me.....with the prospect that the sp should well-exceede 52p it reached recently. Does anyone think it will reach 1 -( not yet I say) - that will need good Trial Results (by all means not "certain") and a good deal on top. They got a good deal from Sanofi and I suspect this reflects the negotiating skills at OXB - it might be expected the execs would accept any decent deal - but this rather shows they are mindful of (us)shareholders. If only other Biotechs were this considerate, eh?
((This post via Ubuntu 6.06 and Firefox 1.05 . . . FWIW))

Recoveing nice and slow.

================================================

Windhover Information to Offer 50-Plus Presenters at 14th Annual Euro-Biotech Forum; Urges Interested Attendees to Register Immediately
May 31 2007, 10:34 AM EST
Business Wire


Windhover Information's 14th Annual Euro-Biotech Forum will host more than 50 exciting biotech companies, who will present to an audience of more than 400 top executives, June 26-28 at the Westin Paris Hotel.

Euro-Biotech is the industry's most targeted one-on-one partnering meeting for American and European life science companies. The Westin Paris has already sold out its reserved rooms for this event, and Windhover urges all interested attendees to register as soon as possible so they can book rooms at the alternate Le Meridien Hotel Etoile.

Further information and online registration for Euro-Biotech are available at www.eurobiotechforum.com.

A premier partnering event

Euro-Biotech, which hosted more than 1,200 one-on-one partnering meetings last year, features Windhover's exclusive online partnering software, which now allows attendees to screen the partnering database for opportunities by multiple criteria:

-- More than 22 therapeutic categories including cardiovascular, oncology, CNS and more

-- Products or technologies

-- Phase of project

-- Market type (specialty or general)

-- Geographic marketing rights desired

-- Molecule type (small molecule, protein, antibody, peptide, or other macromolecule)

-- Mode of administration

More than 50 companies will present their technologies, with new companies being added daily. Presenters to date are Ablynx, Actelion Pharmaceuticals Ltd., Aerovance Inc., Affymax Inc., Alk-Abello A/S, Antisoma PLC , Artisan Pharma, Altea Therapeutics, BioWa, bioXel, Borean Pharma A/S, CardioVascular BioTherapeutics, CombinatoRx, CV Therapeutics, Cyclacel Pharmaceuticals, Endo Pharmaceuticals, ESBATech AG, FibroGen Inc, Genmab, Indevus Pharmaceuticals Inc., KAI Pharmaceuticals Inc., MAP Pharma, MediGene Development, Mutabilis, Nautilus Biotech, Nektar Therapeutics, NeuroSearch A/S, NicOx SA, Novosom AG, Novexel SA, NOXXON Pharma Inc., OctoPlus, Osprey Pharmaceuticals Limited, Osteologix, Oxford BioMedica, PanGenetics B.V., Palau Pharma, Pieris AG, Progenics Pharmaceuticals Inc., Regeneron, Santaris Pharma A/S, Scynexis Inc., Sepracor Inc., Tranzyme Pharma, Vectura Group PLC, XDx and Ziopharm Oncology Inc.

The complete list of presenters, along with information on Windhover's partnering software, is available at www.eurobiotechforum.com.

Companies seeking partnership